Video

Dr. Hope on the Detection Sensitivity of PSMA-PET Scanning

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, (UCSF) discusses the detection sensitivity of PSMA-PET scanning.

Prostate-specific membrane antigen (PSMA)-PET is an imaging study agent that localizes the tumor in about 1 hour. PSMA-PET has a high detection sensitivity and can detect subcentimeter sites in patients that would never have been found otherwise.

Retrospective data, especially from Europe and Australia, indicates how many biochemically recurrent patients have a PSMA avid node. Most of the data show that with a PSMA of <1, you can see a recurrence site in about 60% to 70% of patients, which is better than conventional imaging, such as CT or MRI. Researchers at UCSF recently completed a prospective, FDA-registration phase II/III trial that could be potentially completed by end of 2017.

Related Videos
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami
Richard Kim, MD, Moffitt Cancer Center
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.